of afatinib in combination with docetaxel in patients with advanced solid tumors, known to express EGFR/HER2, who had progressed following prior standard therapies. The study defined the MTD of ...

Drugs that target the EGFR protein and block its activity include: afatinib (Gilotrif) dacomitinib (Vizimpro) erlotinib (Tarceva) gefitinib (Iressa) osimertinib (Tagrisso) The most effective ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib. Complete response of recurrent perihilar ...

NICE has turned down Tagrisso in the past in previously-untreated, EGFR-positive NSCLC but has now given its blessing to that use of the drug, as well as for second-line treatment of patients with ...

afatinib and dacotinib; and third-generation EGFR-TKI, osimertinib, that inhibits both EGFR-sensitive mutations and resistant mutation EGFR T790M. ALK inhibitors included first-generation ...